MDT-AP-1197
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 2.04
- os_event
- false
- age_years
- 2.5
- sex
- F
- new_clusters
- C5
- umap1_2d
- 5.545160133
- umap2_2d
- 4.972100491
- umap1_3d
- 2.764400499
- umap2_3d
- -1.517144667
- umap3_3d
- -2.980996845
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.350
- MYOGENESIS+0.350
- APICAL_SURFACE+0.330
- HYPOXIA+0.220
- GLYCOLYSIS+0.180
- XENOBIOTIC_METABOLISM+0.180
- ESTROGEN_RESPONSE_EARLY+0.170
- PANCREAS_BETA_CELLS+0.170
- HEME_METABOLISM+0.130
- APICAL_JUNCTION+0.110
Top 10 suppressed
- E2F_TARGETS-0.640
- MYC_TARGETS_V1-0.620
- G2M_CHECKPOINT-0.590
- ANDROGEN_RESPONSE-0.350
- MITOTIC_SPINDLE-0.320
- OXIDATIVE_PHOSPHORYLATION-0.320
- MYC_TARGETS_V2-0.300
- DNA_REPAIR-0.280
- ALLOGRAFT_REJECTION-0.270
- UV_RESPONSE_DN-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1121 | Med | Medulloblastoma | 0.859 |
| 2 | BS_7B89YR6K | Posterior Fossa Ependymoma | — | 0.824 |
| 3 | SRR13311177 | — | — | 0.815 |
| 4 | MDT-AP-0759 | Med | Medulloblastoma | 0.804 |
| 5 | SRR1315761 | GTEX | — | 0.802 |
| 6 | MDT-AP-1132 | Med | Medulloblastoma | 0.800 |
| 7 | BS_QV51J756 | Ganglioglioma | — | 0.799 |
| 8 | MDT-AP-0754 | Med | Medulloblastoma | 0.795 |
| 9 | SRR8613724 | — | F | 0.795 |
| 10 | GSM6454739 | — | A | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.350 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.180 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.170 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| PEROXISOME | 0.050 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.010 | Inavolisib | — uncovered |